BACKGROUND A prolonged QT interval corrected for heart rate (QTc) is a major risk factor in patients with long QT syndrome (LQTS). However, heart rate-related risk in this genetic disorder differs among genotypes.
Introduction
The identification of genes associated with congenital long QT syndrome (LQTS) has had a major impact on understanding the molecular basis for ventricular arrhythmias and sudden cardiac death (SCD) in young patients without structural heart disease. 1 Numerous advances have been made in the identification of risk factors for cardiac events in LQTS patients. [2] [3] [4] [5] [6] However, there remains a substantial challenge to explain the widely observed genotype-phenotype variability of this genetic disorder.
A prolonged QT interval corrected for heart rate (QTc) is a major risk factor for cardiac events in LQTS patients, 4, 5, 7, 8 and is usually assessed using the exponential Bazett 9 and Fridericia 10 correction formulas. However, heart rate-related risk of cardiac events in LQTS patients has been shown to occur in a gene-specific manner. 3, 11, 12 Specifically, 82% of the lethal arrhythmic episodes in LQTS type 1 (LQT1) patients, who harbor mutations that impair the I Ks current, are associated with exercise and faster heart rates, whereas in LQTS type 2 (LQT2) patients, in whom I Ks current is normal, symptoms occur mostly during the night or with arousal triggers. 11 This may be because the repolarizing current I Ks activates during increased heart rate, and is essential for QT interval adaptation during tachycardia. 13 Thus, it has been shown that faster heart rates are associated with increased arrhythmic risk in LQT1 patients, 12, 14 and it is possible that the RR interval provides incremental prognostic information to mere assessment of QTc as currently calculated by QT correction formulas, particularly in LQT1 patients with fast resting heart rates.
The present study was designed to evaluate whether risk stratification for life-threatening cardiac events in LQTS patients who carry the common LQT1 and LQT2 genotypes should incorporate a genotype-specific QT correction for heart rate.
Methods

Study population
The study population was drawn from subjects enrolled in the International Long QT Syndrome Registry, 2 for whom follow-up data were available from age 10 through 20 years. Genetic testing was performed on 3,374 members of 443 families enrolled in the registry, and identified 1,309 patients with LQT1 (727 patients from 165 proband-identified families with the KCNQ1 mutations) and LQT2 (582 patients from 176 proband-identified families with the KCNH2 mutations) genotypes. Patients with a mutation in both KCNQ1 and KCNH2 genes were not included in the current analysis. Mutations were identified by standard genetic tests. 15, 16 Informed consent for genetic and clinical studies was obtained from all subjects.
Data collection and management
For each patient, data on personal and family history, cardiac events, and therapy were systematically recorded at each visit or medical contact. Clinical data were recorded on prospectively designed forms and included patient and family history and demographic, electrocardiogram (ECG), therapeutic, and cardiac event information. Upon enrollment in the Long QT Registry, a 12-lead ECG was obtained from each patient. From the first recorded ECG, the duration of the QT and RR intervals were assessed from lead II. The observer who made the QT and RR measurements was blinded to clinical status of patients. Follow-up data regarding ␤-blocker therapy included the starting date, type of ␤-blocker, and discontinuation date in case it occurred. Among patients who died, the use of a ␤-blocker before death was determined retrospectively. The reported analyses used the LQTS analytic database version 18.
End point
The primary end point of the study was time to aborted cardiac arrest (ACA; requiring external defibrillation as part of the resuscitation) or LQTS-related SCD (death abrupt in onset without evident cause, if witnessed, or death that was not explained by any other cause if it occurred in a nonwitnessed setting), whichever occurred first, from age 10 through 20 years. We focused on life-threatening events during adolescence, which is a time period with a high event risk among the LQTS population, as demonstrated previously.
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Repolarization and heart rate measures
We analyzed the risk associated with the following 4 repolarization measures: the absolute QT interval (model 1); the QT interval corrected for heart rate using Bazett's formula (model 2: QTc ϭ QT/RR 1/2 ); the QT interval corrected for heart rate using Fridericia's formula (model 3: QTc[f] ϭ QT/RR 1/3 ); and the QT interval corrected for heart rate using the linear Framingham formula 17 (model 4: QTc-[fram] ϭ 0.154(1 Ϫ RR) ϩ QT). To evaluate the incremental prognostic contribution of heart rate to the analyzed repolarization parameters among carriers of each genotype, all models were analyzed before (models A) and after (models B) further adjustment for the RR interval.
Assessment of an improved QT correction for heart rate Bazett 9 and Fridericia 10 derived their QT correction formulas by regressing log(QT) on log(RR) in a population of normal subjects, and observing that the slope was Ϫ1/2 and Ϫ1/3, respectively. These analyses result in the following log-transformed formulas: log͑QTc͑b͒͒ ϭ log͑QT͒ Ϫ 1⁄2log͑RR͒ ; and log͑QT͑f͒͒ ϭ log͑QT͒ Ϫ 1⁄3log͑RR͒. We fit a Cox model that included both log(QT) and log(RR). If Bazett's formula were optimal for risk stratification among LQT1 and LQT2 genotype carriers, the estimated coefficient on log(RR) should equal Ϫ1/2 times that on log(QT); if Fridericia's formula were to provide optimal risk stratification, then the estimated coefficient on log(RR) would be Ϫ1/3 times that on log(QT). But neither Bazett's nor Fridericia's correction formula was specifically designed for risk stratification based on a specific end point, and it is possible that improved correction for heart rate might differ, depending on the intended use of the correction formula.
Using this methodology we also estimated an improved QT correction for heart rate among carriers of each genotype, by using the derived coefficients from the log(QT) and log(RR) model, using the following formula: QTc ͓new͔ ϭ QT⁄RR ␣ ͑␣ ϭ Ϫ ␤ log͑RR͒ ⁄ ␤ log͑QT͒ ͒. By improved, we refer here to risk stratification for SCD or ACA.
Statistical analysis
The clinical characteristics of study patients by genotype were compared using the 2 test and the Fisher exact test for categorical variables, and the Student t test or the MannWhitney U test for continuous variables.
Cox proportional hazards regression models were used to assess the independent contribution of each of the 4 repolarization measures, with and without further adjustment for the RR interval, to the development of ACA or SCD during follow-up in LQT1 and LQT2 patients. Prespecified covariates included in each of the models were: syncope (defined as transient loss of consciousness that was abrupt in onset and offset), treatment with ␤-blockers, and gender (male age 10 to 15 years). The development of syncope and the administration of ␤-blocker therapy from age 10 through 20 years in an affected individual were evaluated in a timedependent manner. We checked the proportional hazards assumption and found insufficient evidence of any violations of proportional hazards (P Ͼ .05 for each predictor interacted with time), after allowing gender to interact with age, because this particular violation of the proportional hazards assumption has already been well documented in our prior work. 6, 7 In a secondary analysis, we standardized all QTc measures to have the same unit, analyzed hazard ratios (HR) per standard deviation of QTc, and reported these data in the Supplementary Appendix.
To assess and compare the discriminatory ability of the models among carriers of each genotype, we calculated Harrell-Kremers generalized c-index of concordance 18 (http://mayoresearch.mayo.edu/mayo/research/ biostat/upload/80.pdf) for each of the time-dependent adjusted Cox models (without including RR in the models), and compared this with the c-index based on replacing QTc by QTc(new).
Grouped jackknife estimates of standard errors were compared with the standard large-sample estimates assuming independence to determine whether adjusting inferences for the potential dependencies due to family membership seemed necessary.
19 A 2-sided P Ͻ .05 significance level was used for hypothesis testing. The statistical software used for the analyses was SAS version 9.2 (SAS Institute Inc, Cary, NC).
Results
Baseline clinical and ECG characteristics and cardiac events during follow-up in carriers of the LQT1 and LQT2 genotypes are shown in Table 1 . Gender distribution and the frequency of a family history of a LQTS-related SCD were similar in the 2 genotype groups. Baseline heart rates and the corrected QT intervals were similar among LQT1 and LQT2 patients, whereas the absolute QT interval was significantly longer among LQT2 patients as compared with LQT1 patients. The baseline RR and QT intervals were normally distributed in both LQT1 and LQT2 patients (Figure 1) .
Association between repolarization measures and outcome before further adjustment for the RR interval
Multivariate analysis showed that the exponential Bazett formula was the only correction method that independently predicted the risk of life-threatening events among LQT1 patients, whereas among LQT2 patients all analyzed QT correction formulas showed a similar association with outcome (Table 2 ). Thus, among LQT1 patients, 100-ms increments in QTc(b) were associated with a significant 2.8-fold increase in the risk of life-threatening cardiac events, whereas among LQT2 patients 100-ms incre- ECG ϭ electrocardiogram; ICD ϭ implantable cardioverter-defibrillator; LCSD ϭ left cervical sympathetic denervation; LQT1 ϭ long QT syndrome type 1; LQT2 ϭ long QT syndrome type 2; SCD ϭ sudden cardiac death; QTc(b) ϭ corrected QT Bazett formula; QTc(f) ϭ corrected QT Fridericia formula; QTc(fram) ϭ corrected QT Framingham formula. *P Ͻ .05 ments in QTc(b), QTc(f), and QTc(fram) were associated with a similar (2.1-to 2.2-fold) increase in the risk of ACA or SCD (Table 2) .
Association between repolarization measures and outcome after further adjustment for the RR interval
When the RR interval was included as an additional covariate in each of the 4 models, the effects of heart rate were shown to be significantly different between LQT1 and LQT2 patients (Table 2) .
In LQT1 patients, each of the 4 repolarization measures was demonstrated to be a more powerful (Ͼ3-fold risk increase) and significant predictor of outcome in the models that included the RR interval compared with the respective models that did not include heart rate as a covariate. Multivariate analysis in LQT1 patients showed that 100-ms increments in the absolute QT interval were associated with a 3.3-fold increase in the risk of ACA or SCD (P ϭ.020), and 100-ms decrements in the RR interval were associated with a further 1.9-fold increase in the risk (P ϭ .007; Table  2 ). Further adjustment for heart rate improves risk stratification for LQT1 patients, compared with currently used QT correction formulas.
In LQT2 patients, the risk associated with each repolarization measure was similar before and after adjustment for heart rate, and the RR interval was not a significant predictor of outcome in any of the models (Table 2) . Further adjustment for heart rate does not improve risk stratification for LQT2 patients, compared with currently used heart-ratecorrected QT formulas.
Similar results were found when we standardized all QTc measures to have the same unit (standard deviation of each QT-corrected formula) before running the Cox models as reported in the Supplementary Appendix (Tables 1S and 2S) .
A significant heart rate ϫ genotype interaction was shown in the adjusted model that included the absolute QT and RR intervals ( Table 2 ). This finding indicates that the heart rateassociated risk is significantly greater in LQT1 patients (HR ϭ 1.88) as compared with LQT2 patients (HR ϭ 1.11; P value for heart rate ϫ LQT1/LQT2 interaction ϭ 0.036).
Genotype-specific QT correction for heart rate
The ratio of the estimated coefficients on log(RR) and log(QT) in the Cox models were different for LQT1 versus LQT2 patients (Table 3) . In LQT1 patients, the ratio of the estimated coefficients was about 0.8, significantly different from the ratio implied by the correction of either Bazett (0.5) or Fridericia (0.33), neither of which sufficiently corrects for RR. In LQT2 patients, the ratio of the estimated coefficients on log(RR) and log(QT) was about 0.2 (Table  3) . This was not statistically significantly different from the ratio implied by either Bazett's (0.5) or Fridericia's formula (0.33), although it is obviously closer to the Fridericia than to the Bazett correction. Thus, although we have insufficient evidence to reject any of the currently used QTc formulas for LQT2 patients, Fridericia's (and the Framingham) correction appears slightly superior to Bazett's correction, and the data hint that all might slightly overcorrect for heart rate among LQT2 patients.
The differences in the c-indexes between models based on various QTc measures are relatively small in absolute terms, but QTc(new) is the best measure overall; nevertheless, the differences between QTc(new) and other QTc measures are not statistically significant (Supplementary Data, Table 3S ). The mean (SD) values of QT and the various versions of QTc, stratified by whether or not ACA or SCD was observed, are presented in Table 4 . QTc(new) seems better separated as compared with other correction formulas. Among potential dichotomizations of QTc(new), a threshold of 550 ms resulted in the best model fit (the highest c-index) for predicting life-threatening events.
Discussion
Several important clinical implications emerge from the current study of LQTS patients: (1) resting heart rate is an independent predictor of life-threatening cardiac events in LQT1 but not LQT2 patients, with a statistically significant difference in heart rate-related risk between genotypes; (2) current formulas that correct the QT interval duration for heart rate have important limitations for risk assessment in LQT1 patients; and (3) risk stratification for life-threatening cardiac events in LQTS patients may be improved by incorporating a genotype-specific correction of the QT interval for heart rate. The discovery that genes responsible for LQTS encode different ion channels involved in the control of repolarization has led to important advancements in current knowledge regarding genotype-phenotype correlation in hereditary arrhythmogenic disorders. Data from the International LQTS Registry have shown that life-threatening arrhythmias in LQTS patients occur under specific circumstances and in a gene-specific manner. 11 It has been shown that, despite the fact that LQT1 and LQT2 patients harbor mutations that affect the potassium channels, triggers for life-threatening cardiac events among carriers of these 2 genotypes are distinctly different. Patients with the LQT1 genotype have been consistently reported to have a high frequency of arrhythmic events during activities that are associated with increased sympathetic activity and faster heart rates, such as vigorous exercise and swimming, whereas patients with the LQT2 genotype have been shown to be at a relatively low risk during exercise. 11, [20] [21] [22] The difference in heart rate-related risk between genotypes may re- flect that different potassium currents are involved in these 2 LQTS genotypes. I Ks shortens ventricular repolarization with fast heart rates and catecholamines; in LQT1, there is a reduction in this compensatory response. Fast heart rates have been shown to lead to accumulation of I Ks , even in the absence adrenergic stimulation. 13 Thus, impaired I Ks accumulation in LQT1 patients, as a result of malfunction of channels containing a mutant subunit, may contribute to reduced adaptation of action potential duration to increasing heart rates. This concept is supported by an experimental model for LQT1 in which I Ks blockade greatly enhances the probability of torsades de pointes in the presence of catecholamines, 23 and by the fact that LQT1 patients have an exaggerated QTc interval prolongation during physical activity. 24 Our findings are consistent with previous observations regarding the effect of impaired I Ks function on the relationship between heart rate and the duration of ventricular repolarization in LQT1 patients. However, in contrast to previous studies that evaluated the QT-RR relationship during exercise testing, 24, 25 we have shown that increasing resting heart rate is an independent risk factor for lifethreatening cardiac events in LQT1 patients. In addition, Schwartz et al 12 and Brink et al 14 have previously reported that resting heart rate plays a significant modulating role on the risk for cardiac events among carriers of a specific KCNQ1 mutation (A341V); the present study extends these findings to a wide range of KCNQ1 mutation carriers.
Importantly, although the Bazett's correction formula was identified in the present study as the best predictor of life-threatening events among known formulas for LQT1 patients, our data suggest that currently available QT corrections for heart rate do not provide sufficient risk assessment among carriers of the LQT1 genotype. We have shown that risk assessment among carriers of this genotype can be improved by incorporating a genotype-specific QT correction formula that assumes a more linear relationship between the duration of ventricular repolarization and heart rate than that provided by QTc(b) or QTc(f). Our data demonstrate a significant heart rate ϫ genotype interaction effect, indicating that the risk associated with resting heart rate is significantly different between LQT1 and LQT2 patients. Thus, in LQT2 patients, in whom I Ks function is not affected, a QTc exponential formula of QT/RR 0.2 seems to describe accurately the relationship between heart rate and ventricular repolarization, whereas in LQT1 patients risk stratification is improved by using a much stronger QT/RR 0.8 correction formula. All models in the present study were adjusted for baseline and time-dependent risk factors and showed that a 100-ms increase in QTc [new] was associated with 2.9-fold (P ϭ.004) and 2.1-fold (P ϭ .013) increased risk for ACA/SCD among LQT1 an LQT2 patients respectively, in addition to the effects of gender, time-dependent syncope, and ␤-blockers.
When a baseline ECG is assessed in a nongenotyped LQTS patient, we suggest using Bazett's correction formula; however, an important implication for a patient who has been diagnosed as a carrier of the LQT1 genotype would be that the RR interval provides incremental prognostic information to mere assessment of QTc by Bazett's correction formula. Thus, we recommend using the improved QT correction formulas when the specific genotype is known. It should be noted that any given value of QTc means something different for each ACA ϭ aborted cardiac arrest; LQT1 ϭ long QT syndrome type 1; LQT2 ϭ long QT syndrome type 2; SCD ϭ sudden cardiac death; QTc(b) ϭ corrected QT Bazett formula; QTc(f) ϭ corrected QT Friderichia formula; QTc(fram) ϭ corrected QT Framingham formula. *Hazard ratios are per 100-ms increase in the QT and QTc intervals; and per 100-ms decrease in the RR interval; findings in each model were also adjusted for the additional covariates: time-dependent syncope, gender (male age 10 to 15 years), and time-dependent medical therapy with ␤-blockers. 
Study limitations
In the present study, we evaluated risk factors for LQTSrelated life-threatening cardiac events during adolescence, a time period that has been shown to be associated with the highest event rate in patients with this genetic disorder 7 and when heart rates are usually faster than 60 beats/min. However, the phenotypic expression of LQTS has been shown to be age dependent. 7, 8 Thus, it is possible that the risk associated with heart rate may be different in older LQTS patients. Further studies are needed to validate the current findings in different age groups of affected LQTS patients.
Because of sample size limitations, we did not exclude patients treated with ␤-blockers; nevertheless, all multivariate models included adjustment for time-dependent ␤-blocker therapy. In a secondary analysis excluding patients treated with ␤-blockers, we observed consistent results regarding the QT-RR relationship and the suggested improved QT correction formulas among LQT1 and LQT2 patients. Our study is underpowered to assess the yield of the new formulas and event rates within fixed time periods by dichotomizing survival time and is also underpowered to calculate the sensitivity and specificity of the new formulas.
The current study population, despite being the largest genotyped population to assess QT/RR relation to arrhythmic risk, is not sufficient for validation of specific correction formulas without validations in independent populations. The present study is an overall risk assessment, whereas in clinical practice, risk assessment should be individualized because some lethal events can occur in LQT1 patients in the absence of rapid heart rate. QTc alone should not be viewed as a complete diagnostic test because there are several other important and known risk factors.
Conclusion
Investigations of clinical aspects and basic causal mechanisms of LQTS have provided novel and important insights into the fundamental nature of the electrical activity of the human heart and into the relationship between disturbances in ion flow and cardiac disease. Our findings suggest that an understanding of the genotype-phenotype relationship in this genetic disorder can lead to improved criteria for risk stratification for life-threatening arrhythmic events in affected patients.
